Comparative Clinical Outcomes of Edoxaban in Adults With Nonvalvular Atrial Fibrillation

Conclusions: Edoxaban is a welcome addition to the NOAC's armamentarium. However, the comparative data with other novel NOACs are mostly nonexisting, and urgently needed for better individual patient assessment.
Source: American Journal of Therapeutics - Category: Drugs & Pharmacology Tags: Reviews Source Type: research